Skip to content

Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)

Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00373841
Acronym
GAP
Enrollment
500
Registered
2006-09-08
Start date
2005-10-01
Completion date
2030-07-01
Last updated
2026-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Pulmonary Fibrosis

Keywords

Lung, Fibrosis, Idiopathic, Biomarkers, Genomics, Longitudinal

Brief summary

The purpose of the study is to identify genetic and biologic markers that may predict the loss of lung function due to idiopathic pulmonary fibrosis. The studies will compare genetic and biologic markers of samples to changes in symptoms. The ultimate goal is to predict if or when patients are likely to experience a rapid decline in lung function due to disease progression.

Detailed description

People who are diagnosed with idiopathic pulmonary fibrosis are asked to participate in this study. The subject must be treated at the Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease. Subjects, if consented, are required to perform tests so that research data can be collected. At the initial visit, patients are subject to having a blood draw, pulmonary function testing, echocardiograms, and CT scans as well as completing several questionnaires designed to measure how the patient is feeling. Follow up visits are then scheduled in 3-4 month intervals. Every 3-4 months blood samples will be collected while every 6-8 months the questionnaires will administered. If the patient enters a stage of accelerated decline in lung function, a bronchoscopy will be performed to collect residual bronchoalveolar lavage fluid for testing. All of the results of clinical and laboratory testing will be placed into the subjects research file.

Interventions

None listed

Sponsors

University of Pittsburgh
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who are 18 or older * Diagnosis of Idiopathic Pulmonary Fibrosis * Treated at the Simmons Center

Exclusion criteria

* Other Lung Illness

Countries

United States

Contacts

CONTACTMichelle MacPherson, MAT
macphersonmj@upmc.edu412-647-4537
CONTACTMichelle Meyers, BSN RN
meyersma@upmc.edu412-692-2149
PRINCIPAL_INVESTIGATORKevin F Gibson, MD

University of Pittsburgh - Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 28, 2026